MedWatch

Biotech billionaire appoints Dane as CEO of growing drug group

After two months as chair of the board in Swedish Karo Pharma, Bo Jesper Hansen has replaced the company's CEO. The new top manager is to "create a different kind of company" and expand the firm outside the Nordic countries.

Christoffer Lorenzen takse position as CEO in Karo Pharma on July 1, 2019. | Foto: Ritzau Scanpix/Niels Hougaard

Danish biotech billionaire Bo Jesper Hansen, who earned his fortune by merging his firm Swedish Orphan and Biovitrum and sell his shares, does not rest on his laurels.

After few months as chairman in Swedish drug group Karo Pharma, he has already replaced the company's CEO.

Læs hele artiklen

Få 14 dages fri adgang.
Det kræver intet kreditkort.

  • Adgang til alle låste artikler
  • Modtag vores daglige nyhedsbreve
  • Fuld adgang til vores app
Der skete en fejl. Prøv venligst igen senere

Få fuld adgang til dig og dine kollegaer.

Start et gratis virksomhedsprøveabonnement

Mere fra MedWatch

Seneste nyt

Ledige job

Se flere jobs

Se flere jobs

Latest news

Seneste nyt fra Watch Medier